Skip to content
Research archive

Research Articles

Meta-Analysis

Efficacy and effectiveness of anti-CGRP monoclonal antibodies treatment in the prevention of cluster headache attacks: A systematic review and meta-analysis.

Anti-CGRP Monoclonal Antibodies Show Significant Benefit in Episodic Cluster Headache Prevention — A systematic review and meta-analysis of 25 studies found that anti-CGRP monoclonal antibodies significantly improved the 50% responder rate in episodic cluster headache compared to placebo, reflecting about 65% higher odds of meaningful attack reduction (OR = 1.

Apr 16, 2026 · Cephalalgia · Immunology
83
Clinical Trial

A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer’s disease.

SAMe 400 mg Daily Fails to Reduce Plasma P-Tau217 in Alzheimer's Disease Trial — A six-month placebo-controlled trial found no statistically significant reduction in plasma phosphorylated tau (p-tau217) among people with Alzheimer's disease taking SAMe 400 mg daily, with a standardized mean difference of 37.

Apr 15, 2026 · Alzheimers Dement · Neurology
87
Research Article

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.

Darolutamide Delays Pain Progression and Quality-of-Life Decline in Metastatic Hormone-Sensitive Prostate Cancer — In men with metastatic hormone-sensitive prostate cancer, darolutamide added to androgen deprivation therapy reduced the risk of pain progression by approximately 28% compared to placebo plus ADT, and delayed meaningful deterioration in overall wellbeing by roughly 24%, as measured by validated patient-reported outcome tools.

Apr 15, 2026 · Lancet Oncol · Oncology
87
Clinical Trial

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Deutenzalutamide Reduces Progression Risk by 42% in Heavily Pretreated Prostate Cancer — In a randomized, placebo-controlled phase III trial, deutenzalutamide 80 mg daily reduced the risk of radiographic disease progression by approximately 42% compared to placebo in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone and docetaxel (HR 0.

Apr 14, 2026 · Signal Transduct Target Ther · Oncology
85
Clinical Trial

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Penpulimab Plus Chemotherapy Cuts Progression Risk by 55% in First-Line Metastatic Nasopharyngeal Carcinoma — In a randomized, double-blind phase 3 trial, adding the anti-PD-1 antibody penpulimab to platinum-based chemotherapy reduced the risk of disease progression or death by approximately 55% compared with chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma (median PFS 9.

Apr 14, 2026 · Signal Transduct Target Ther · Oncology
87
Clinical Trial

ENAC blockade reduces blood pressure and arterial stiffness in adults with obesity and insulin resistance.

Low-Dose Amiloride Reduces Arterial Stiffness and Blood Pressure in Adults With Metabolic Syndrome — In a 24-week randomized controlled trial, low-dose amiloride (5 mg daily) significantly reduced arterial stiffness as measured by carotid-femoral pulse wave velocity (cfPWV) and lowered systolic blood pressure by a mean of 5.

Apr 13, 2026 · Am J Physiol Heart Circ Physiol · Cardiology
81
Clinical Trial

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Triplet KRd Maintenance Nearly Doubles Progression-Free Survival Over Lenalidomide Alone Post-Transplant — In a randomised phase 3 trial, carfilzomib-lenalidomide-dexamethasone (KRd) reduced the risk of disease progression or death by approximately 54% compared with lenalidomide monotherapy in newly diagnosed multiple myeloma patients following autologous stem-cell transplantation (median PFS 72.

Apr 13, 2026 · Lancet Haematol · Infectious Diseases
83
Review

Effect of vitamin D3 supplementation on systemic inflammation and disease-specific markers in patients with autoimmune diseases: a comprehensive meta-analysis of randomized controlled trials.

Vitamin D3 Reduces Inflammation Modestly in Autoimmune Diseases But Does Not Alter Core Disease Activity — A meta-analysis of 27 randomized controlled trials found that vitamin D3 supplementation substantially raised serum 25(OH)D levels (WMD: 53.

Apr 12, 2026 · Inflammopharmacology · Immunology
81
Clinical Trial

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.

Hetrombopag Achieves Platelet Response in 61% of Pediatric ITP Patients vs 10% Placebo — In a placebo-controlled phase 3 trial, once-daily oral hetrombopag produced platelet counts of at least 50 × 10⁹/L at Week 10 in 61.

Apr 12, 2026 · J Hematol Oncol · Pediatrics
88